sonomapharma.com (SNOA) - מקדם חוב לטווח ארוך להון

This daily price chart for Sonoma Pharmaceuticals (SNOA) illustrates the dynamics of a company whose US-based plants produce hypochlorous acid-based tissue healing agents. The individual long-term debt metric stands at 0.07. The business relies on proprietary molecular stabilization, which ensures steady demand for its unique dermatological products. A staff of experienced biochemists and the targeted hiring of clinical research experts guarantee stable development.

Professional asset selection requires assessing financial stability through the lens of debt load. This metric measures the proportion of liabilities with a maturity exceeding one year relative to total equity. For Sonoma Pharmaceuticals (SNOA), the value 0.07 reflects the balance between debt financing and the protection of Microcyn patents under strict FDA oversight. Analyzing the long-term debt-to-equity ratio allows for an assessment of bankruptcy risks against the efficiency of financial leverage.